Ladurot

Tamsulosin hydrochloride and dutasteride, the active ingredient in Ladurot, is a alpha‑1 adrenergic antagonist / 5‑alpha‑reductase inhibitor presented as an oral tablet formulation for oral use. It treats benign prostatic hyperplasia in adult men by relieving urinary obstruction.

GNH USA supplies Ladurot as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ladurot combines tamsulosin and dutasteride to manage benign prostatic hyperplasia (BPH) and its associated urinary symptoms. - Benign prostatic hyperplasia (BPH): reduces prostate size and relaxes smooth muscle to improve urinary flow. - Lower urinary tract symptoms (LUTS) due to BPH: alleviates urgency, frequency and nocturia. - Prostate enlargement: decreases dihydrotestosterone‑driven growth, helping to prevent disease progression.

Ladurot may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Dizziness or light‑headedness. - Abnormal ejaculation or reduced libido. - Headache. - Nasal congestion. - Breast tenderness or enlargement.

Serious or Rare Side Effects: - Intraoperative floppy iris syndrome, which can complicate cataract surgery. - Severe allergic reactions such as rash, swelling or anaphylaxis. - Marked hypotension leading to fainting.

Before prescribing Ladurot, clinicians should consider several precautionary measures. - Renal or hepatic impairment: monitor liver function and adjust therapy if needed. - History of prostate cancer: evaluate risk‑benefit, as dutasteride may affect tumor markers. - Concurrent antihypertensive therapy: watch for additive blood‑pressure lowering effects. - Known hypersensitivity to tamsulosin, dutasteride or any excipients: avoid use. - Planned cataract surgery: inform surgeon of tamsulosin use due to risk of floppy iris syndrome. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Ladurot can interact with other medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise dutasteride plasma levels. - Other α‑blockers (e.g., prazosin, doxazosin): can cause additive hypotension.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase tamsulosin exposure. - Additional 5‑alpha‑reductase inhibitors (e.g., finasteride): may enhance hormonal effects. - Diuretics: may intensify orthostatic blood‑pressure drops.